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Cowpox virus encodes an extensive array of putative
immunomodulatory proteins, likely contributing to
its wide host range, which includes zoonotic infec-
tions in humans. Unlike Vaccinia virus, cowpox virus
prevents stimulation of CD8+ T cells, a block that
correlated with retention of MHC class I in the endo-
plasmic reticulum by the cowpox virus protein
CPXV203. However, deletion of CPXV203 did not
restore MHC class I transport or T cell stimulation.
Here, we demonstrate the contribution of an addi-
tional viral protein, CPXV12, which interferes with
MHC class I/peptide complex formation by inhibiting
peptide translocation by the transporter associated
with antigen processing (TAP). Importantly, human
and mouse MHC class I transport and T cell stimula-
tion was restored upon deletion of both CPXV12 and
CPXV203, suggesting that these unrelated proteins
independently mediate T cell evasion in multiple
hosts. CPXV12 is a truncated version of a putative
NK cell ligand, indicating that poxviral gene frag-
ments can encode new, unexpected functions.
INTRODUCTION
The eradication of Variola virus (VARV), the cause of smallpox, in
1977 left cowpox virus (CPXV) and monkeypox virus (MPXV) as
the predominant remaining infectious orthopoxviruses (OPXVs)
causing human disease through zoonosis (Lewis-Jones, 2004).
MPXV is second to VARV with regard to virulence, with symp-
toms similar to smallpox and mortality rates reaching almost
10%. The less virulent CPXV is endemic in Europe, with occa-
sional transmission via direct contact with infected domestic
animals (Baxby and Bennett, 1997). In contrast to VARV, which
was restricted to humans, both MPXV and CPXV infect many
different mammal species, which renders their eradication
impossible. This wide host range implies that these viruses areCell Hostparticularly adept at evading immune responses of many
species.
We previously reported that CD8+ T cells obtained from mice
infected with CPXV were not stimulated in the presence of
CPXV-infected target cells (Dasgupta et al., 2007). In contrast,
T cell stimulation was observed in the presence of vaccinia virus
(VACV)-infected targets, suggesting a CPXV-specific immune
evasion mechanism. This mechanism was not restricted to
rodents, since T cells from vaccinated humans were similarly
stimulated by VACV but not by CPXV. T cell evasion correlated
with the observation that major histocompatibility complex class
I (MHC class I) molecules were retained in the endoplasmic retic-
ulum (ER) by CPXV, whereas maturation was unimpaired in
VACV-infected cells. However, it remained to be demonstrated
whetherMHCclass I retention was responsible for T cell evasion,
particularly since we did not observe such a correlation for
MPXV, which inhibited T cell stimulation independent of MHC
class I downregulation (Hammarlund et al., 2008).
The differential T cell stimulation between CPXV and VACV
suggested that CPXV encodes a specific immunomodulator
absent from the genome of VACV. Indeed, the CPXV-specific
open reading frame (ORF) 203 retains MHC class I in the ER
via a C-terminal ‘‘KTEL’’ ER-retrieval motif (Byun et al., 2007).
However, deletion ofCPXV203 only partially restoredMHC class
I trafficking, suggesting that CPXV expressed at least one
other gene product inhibiting MHC class I maturation. Here, we
identify CPXV12 as the second ORF responsible for MHC class
I inhibition. We demonstrate that the combined deletion of
CPXV12 with CPXV203 restores both MHC class I expression
and T cell stimulation by CPXV-infected cells, suggesting that
interference with MHC class I maturation is responsible for
T cell evasion by CPXV. We further demonstrate that CPXV12
retains MHC class I by inhibiting transporter associated with
antigen processing (TAP)-dependent peptide translocation and
thus assembly with peptides in the ER. Interestingly, CPXV12
of the Brighton Red (BR) strain studied here is a truncated
version of D10L, a C-type lectin domain-containing protein en-
coded by the GRI and GER-91 strains of CPXV. However, only
the truncated version interferes with MHC class I, whereas the
full-length version is a putative ligand for the NK cell-inhibitory
receptor NKR-P1B. Our data thus identify a poxviral TAP& Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc. 433
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beyond the herpesvirus family. The data further imply that trun-
cated ORFs found in many poxviral genomes can encode new,
unexpected functions.
RESULTS
CPXV12 Downregulates MHC Class I
Given our finding that MPXV does not retain MHC class I (Ham-
marlund et al., 2008), despite the presence of a CPXV203 ortho-
log (Byun et al., 2007), we hypothesized that additional MHC
class I inhibitors of CPXV should be absent from both VACV
and MPXV. We further hypothesized that the new ORF should
contain a transmembrane domain (TMD), since MHC class I
was retained in the ER of CPXV-BR (Dasgupta et al., 2007) and
the CPXV203-deleted virus D203 (Byun et al., 2007). Genomic
comparison of MPXV-Zaire1979 and VACV-WR with CPXV-BR
revealed a short list of TMD-containing ORFs found only in
CPXV: 1, 7, 12, 47, 63, and 214 (http://www.poxvirus.org).
Upon transient expression of each ORF in HeLa cells, CPXV12
significantly reduced MHC class I surface levels (Figure 1A),
whereas all other transfectants showed unaltered MHC class I
expression (data not shown). We further observed that CD44
levels were not reduced, consistent with CPXV12 being MHC
class I specific (Figure 1A).
CPXV12 encoded by the CPXV-BR strain represents a 69
amino acid (aa) truncated version of the ORF D10L that com-
prises 96 aa in strain GRI and 160 aa in strain GER-91 (http://
www.poxvirus.org) (Figure 1B). The 160 aa version of this protein
has similarity to C-type lectin ligands for NKR-P1 NK cell-inhib-
itory receptors (Voigt et al., 2007). However, the C-type lectin
domain is missing from the truncated CPXV12 of BR, which
only shares the N-terminal 46 aa with D10L of GER-91 and GRI
strains (Figure 1B). Given this limited overlap, we wanted to
know whether the full-length D10L protein from strain GER-91
or the 96 aa variant in GRI inhibited MHC class I expression.
N-terminally epitope-tagged, codon-optimized (CO-N-FLAG)
versions of CPXV12, D10L-GER, or D10L-GRI were transfected
into HeLa cells, and surface expression of MHC class I as well
as intracellular expression of the viral proteins was determined
by flow cytometry. As shown in Figure 1C, while the CO-N-
FLAG version of CPXV12 (BR) downregulated MHC class I,
Figure 1. CPXV12 Downregulates MHC Class I Surface Expression
(A) Flow cytometry of MHC class I surface levels in the presence of CPXV12. HeLa cells were transiently transfected with either pCPXV12 (red) or empty vector
(green). At 48 hr posttransfection, cells were stained with anti-HLA-A,B,C or anti-CD44 and analyzed by flow cytometry. Solid gray line represents isotype control.
(B) Amino acid alignment of CPXV12 and its orthologs, CPXVD10L (GRI) and CPXVD10L (GER-91). Identical residues are highlighted in yellow. Underlined
residues represent the C-type lectin-like domain.
(C) Flow cytometry of MHC class I surface levels in the presence of CPXV12 and CPXVD10L. pCPXV12-N-FLAG, pCPXV12-C-FLAG, pCPXV12CO-N-FLAG,
pCPXVD10L (GER)-N-FLAG, and pCPXVD10L (GRI)-N-FLAG were transiently transfected into HeLa cells. The cells were incubated for 48 hr and stained with
either HLA-specific antibodies (unpermeabilized cells) or anti-FLAG antibodies (permeabilized cells).434 Cell Host & Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc.
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levels. Thus, the short ORF expressed by BR acquired a new
function that is different from its full-length ancestral protein.
Since the N-terminal 46 aa are highly conserved (70% identity)
between the D10L and CPXV12, these data further suggested
that the N terminus, including the TMD, is not sufficient to down-
regulate MHC class I. Instead, the mutations acquired in the 30
end seem to be essential for MHC class I interference. Moreover,
epitope tagging of the C terminus (C-FLAG) rendered CXPV12
nonfunctional despite increased protein levels compared to the
N-terminally tagged native sequence (N-FLAG) (Figure 1C).
CPXV12 Is an ER-Resident Type II Transmembrane
Protein
The full-length D10L protein is expected to be surface-ex-
pressed with a type II transmembrane topology similar to related
proteins of mammalian hosts and of rat cytomegalovirus (Voigt
et al., 2007). Since the N terminus, including the TMD, is highly
conserved in CPXV12, the type II topology is expected to be
conserved (Figure 2A). To test this hypothesis, we performed
a protease protection assay by in vitro translating CPXV12 in
the presence of microsomes. Preprolactin was used as control,
since it undergoes a characteristic shift in electrophoretic
mobility upon translocation due to cleavage of the leader peptide
by the signal sequence peptidase (Figure 2B). As expected, only
the cleaved prolactin cosedimented with the microsomes,
whereas preprolactin as well as the cytosolic cyan fluorescent
protein (CFP) were not enriched in microsome pellets. Similar
to prolactin, CPXV12 cosedimented with microsomes and was
protected from protease digestion (Figure 2B). However, the
MW did not change in the presence of microsomes, consistent
with a noncleavable signal sequence. In contrast, a small MW
reduction was observed upon protease treatment, suggesting
that the short N terminus is exposed to the cytosol. We therefore
conclude that CPXV12 most likely displays a type II transmem-
brane topology (Figure 2A).
To determine the subcellular localization of CPXV12, we per-
formed immunofluorescence (IF) analysis of CPXV12 in trans-
fected HeLa cells. CPXV12 N-FLAG was costained with markers
of the ER, ER-Golgi intermediate compartment (ERGIC), or the
Golgi. While the Golgi protein giantin stained a subcellular struc-
ture that was distinct from CPXV12, ERGIC-53 partially overlap-
ped, whereas the ER protein calreticulin completely overlapped
with FLAG staining (Figure 2C). Similarly, the ER proteins cal-
nexin and protein-disulfide isomerase colocalized with CPXV12
(data not shown). Therefore, we conclude that CPXV12 locates
to the ER. Pulse-chase experiments further revealed that the
FLAG-CPXV12 has a half-life of approximately 2 hr, suggesting
that CPXV12 is short-lived (Figure 2D). Taken together, these
data suggest that CPXV12 is a short-lived, ER-resident type II
transmembrane protein.
CPXV12 and CPXV203 Are Responsible
for MHC Class I Downregulation by CPXV
To determine whether CPXV12 was responsible for the residual
MHC class I retention reported for CPXV lacking ORF203 (D203)
(Byun et al., 2007), we generated a recombinant virus lacking
both CPXV203 and CPXV12 (Figures 3A and 3B; Supplemental
Data). The double knockout (DKO) virus did not show any growthCell Hostdefect in vitro (data not shown). We compared MHC class I
surface levels in mouse and human cells infected with wild-
type (WT) CPXV-BR, the single knockout (SKO) viruses D12 or
D203 (Byun et al., 2007), and D12D203. As described previously
(Dasgupta et al., 2007), WT CPXV reduced MHC class I surface
levels compared to uninfected human (THFs) or mouse (MC57)
fibroblasts (Figure 3C). Decreased MHC class I was also
observed on cells infected with the SKO viruses. In contrast,
MHC class I levels remained high in cells infected with the
DKO virus despite comparable infection as monitored by GFP
expression. These observations are consistent with CPXV12
and CPXV203 each independently interfering with MHC class I
surface expression.
Deletion of CPXV12 and CPXV203 Restores
T Cell Stimulation
We previously demonstrated that ER retention of MHC class I by
CPXV correlated with a lack of stimulation of T cells derived from
either VACV-immune humans or CPXV-infected mice (Dasgupta
et al., 2007). In contrast, infection of antigen-presenting cells
(APCs) by VACV-WR stimulated both human and murine
OPXV-specific CD8+ T cells, and VACV did not interfere with
MHC class I transport. To determine if MHC class I downregula-
tion by CPXV203 and CPXV12 was responsible for inhibiting
T cell stimulation, we monitored cytokine production by VACV-
specific T cells in the presence of APCs infected with WT or
recombinant CPXV or VACV-WR.
BALB/c mice were infected with VACV, and the splenic CD8+
T cell response against target cells (A20 cells) infected with
CPXV, D12, D203, D12D203, or VACV was analyzed 8 days
later by intracellular cytokine staining (ICCS). A representative
example is shown in Figure 4A, whereas Figure 4B shows the
average results from six mice. As reported previously (Dasgupta
et al., 2007), a large percentage of CD8+ T cells produced IFNg in
response to VACV-infected targets, whereas less than 1% of
CD8+ T cells responded to CPXV-infected targets. Similarly,
both SKO viruses showed a diminished T cell response, although
at a significantly higher frequency than WT virus, particularly
D203 that expresses CPXV12 only. However, more than 70%
of CD8+ T cells responding to VACV-infected cells also re-
sponded to A20 cells infected with D12D203 (Figure 4B), indi-
cating that the majority of VACV-specific T cells were able to
recognize DKO-infected targets. Thus, deletion of both MHC
class I inhibitors restored T cell stimulation.
To determine whether CPXV12 and CPXV203 were also
responsible for the previously reported evasion of T cells ob-
tained from vaccinated humans (Dasgupta et al., 2007), we in-
fected peripheral blood mononuclear cells (PBMCs) from
VACV-immune subjects with CPXV, D12, D203, D12D203, or
VACV for 18 hr and determined the frequency of stimulated
virus-specific CD8+ T cells by ICCS. Figure 4C depicts the
ICCS results for one individual, whereas Figure 4E shows the
average results from four individuals. Comparable infection of
monocytes within the PBMCs by all strains was verified by stain-
ing for OPXV proteins (Figure 4D). VACV-infected cells induced
significant CD8+ T cell responses, as monitored by IFNg and
TNF-a production, in all tested individuals, whereas T cell
responses against CPXV-, D12-, and D203-infected cells was
sharply reduced (Figures 4C and 4E). In contrast, T cell& Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc. 435
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A Poxviral TAP InhibitorFigure 2. CPXV12 Is a Short-Lived, ER-Resident Type II Transmembrane Protein
(A) Model of CPXV12 topology in the ER membrane.
(B) In vitro translation of CPXV12 mRNA in the presence of microsomes. In vitro transcribed mRNAs encoding CPXV12 and control proteins, CFP, and prolactin
were added to a rabbit reticulocyte translation system in the presence of caninemicrosomalmembranes. Left panel: Total translation products or products recov-
ered after microsome pelleting. Right panel: Following translation, pelleted microsomal fractions were treated with Proteinase K and separated by SDS-PAGE.
Molecular weight markers (kDa) are shown.
(C) Subcellular localization of CPXV12. HeLa cells were transiently transfected with pCPXV12-N-FLAG. After 48 hr, cells were fixed, permeabilized, and stained
with antibodies specific to calreticulin, ERGIC53, giantin, or FLAG.
(D) CPXV12 half-life by pulse-chase. pCPXV12-CON-FLAG and empty vector control (Mock) were transiently transfected into HeLa cells. At 24 hr posttransfec-
tion, cells were pulse-labeled for 1 hr and the label was chased for the indicated time. Lysates were immunoprecipitated with anti-FLAG, separated by SDS-
PAGE, and visualized by autoradiography (left panel). Optical density of CPXV12-specific bands was measured and plotted against the chase time (right panel).436 Cell Host & Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc.
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D12D203. These observations correlated with MHC class I
downregulation measured on CD14+ OPXV-infected APCs by
CPXV and the SKO viruses, but not by D12D203 (Figure 4F).
Taken together, these data indicate that T cell evasion is caused
by MHC class I downregulation mediated independently by
CPXV203 and CPXV12. Remarkably, each of these gene prod-
ucts inhibits T cell stimulation of both human and mouse
T cells, consistent with the ability of CPXV to infect many
mammalian hosts.
CPXV12 Inhibits MHC Class I Transport
CPXV retains MHC class I in the ER of human cells (Dasgupta
et al., 2007), and murine MHC class I was retained by D203
(Byun et al., 2007). To determine whether CPXV12 was respon-
sible for MHC class I retention byD203, we examinedMHC class
I assembly and maturation in murine and in human cells infected
with single or double KO viruses.
Murine MC57 fibroblasts, mock infected or infected with
CPXV,D12,D203, orD12D203 for 6 hr, were pulse-chase labeled
and immunoprecipitated with an antibody specific for H2-Kb. As
Figure 3. CPXV12 Contributes to MHC Class I Downregulation by CPXV
(A) Schematic design of D12 and D12D203 mutant viruses.
(B) PCR analysis ofD12 andD12D203mutants. Purified viral genomic DNA ofWTCPXV,D12, andD12D203 was PCR amplified with primers specific for CPXV12,
CPXV203, or CPXV214. PCR products were separated by gel electrophoresis.
(C) Flow cytometry of MHC class I surface expression. THF (left) and MC57 (right) cells were infected with WT CPXV, D12, D203, and D12D203. At 24 hr
postinfection, cells were stained with either HLA-A,B,C or H2-Kb-specific antibodies.Cell Host & Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc. 437
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EndoH sensitivity, in cells infected with WT and both SKO
viruses. In contrast, MHC class I acquired EndoH resistance in
DKO-infected cells similar to the mock-infected cells. ER reten-
tion of HLA-A3 by SKO viruses was also observed in transfected
HeLa cells, whereas theDKO virus did not impede its intracellular
Figure 4. CD8+ T Cell Activation by CPXV Is Restored upon Deletion of Both CPXV12 and CPXV203
(A) The antiviral CD8+ T cell response in BALB/c mice measured by ICCS. Splenocytes (8 days postinfection) were incubated with uninfected A20 cells or
infected with the indicated viruses. The percentage of IFNg-producing CD8+ T cells (upper right quadrant) was determined after background subtraction
(uninfected control).
(B) The average antiviral CD8+ T cell response of six mice was determined by ICCS and normalized to 100% based on the response to VACV. The data are
representative of two experiments with three mice per group (±SD). Statistical differences were calculated using the two-tailed paired Student’s t test.
(C) Human virus-specific CD8+ T cell responses in the presence of indicated viruses. PBMCs of VACV-immune subjects were gated onCD8+CD4 T cells, and the
number of IFNg+TNF-a+CD8+ T cells per 106 CD8+ T cells (upper right quadrant) was determined after background subtraction (uninfected control). The CD8+
T cell responses from a representative subject at 2 months after VACV infection are shown.
(D) The number of virus-infected CD14+ monocytes in a representative PBMC sample at 16 hr postinfection was determined by staining with polyclonal
antibodies against OPXV antigens. The numbers in the upper right quadrants represent the percentage of virus-infected CD14+ cells after background subtrac-
tion (uninfected).
(E) The average antiviral CD8+ T cell response from four subjects (±SD) was determined by ICCS at 2months post-VACV infection and normalized to 100%based
on the response to VACV.
(F) HLA-A,B,C expression on virus-infected primary CD14+ monocytes at 16 hr postinfection. Monocytes were identified based on forward and side scatter
characteristics and CD14 expression.438 Cell Host & Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc.
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pendently interferes with MHC class I maturation. Since MHC
class I transport was restored upon deletion of both ORFs, we
conclude that CPXV12 was responsible for the remaining MHC
class I retention reported for D203 (Byun et al., 2007). To further
examine whether CPXV12 was sufficient for MHC class I reten-
tion, we inserted CPXV12 into Modified Vaccinia Ankara (MVA)
(Figure S1). MC57 cells infected with MVA or MVA-CPXV12
were labeled, and Kb was immunoprecipitated. As shown in
Figure 5C, Kb remained EndoH sensitive in MVA-CPXV12 during
the 2 hr chase period compared to MVA or uninfected cells,
consistent with CPXV12 being sufficient for MHC class I reten-
tion.
In addition to ER retention, we observed reduced amounts of
MHC class I reactive with conformation-specific antibodies
recognizing fully assembled, peptide-loaded H2-Kb (Y3), HLA-
A3 (GAP), or HLA-A,B,C (W6/32) in the presence of CPXV12.
This was particularly pronounced for endogenous MHC class I
when HeLa cells were infected with CPXV12-expressing viruses
(Figure 5D) or transfected with CPXV12-expressing plasmid
(Figures 5E and 5F). In contrast, viruses that expressed only
CPXV203 or transfection with CPXV203 did not affect the total
levels of peptide-loaded MHC class I molecules (Figure 5F),
although cell surface expression was highly reduced. These
results suggested that, unlike CPXV203 that retains MHC class
I by physical association and continuous retrieval via the
KDEL-receptor, CPXV12 impaired the assembly of peptide-
loaded MHC class I.
CPXV12 Inhibits MHC Class I Assembly with Peptides
MHC class I molecules are heterotrimers consisting of heavy
chain (HC), b2-microglobulin (b2 m), and peptide. The reduced
amount of MHC class I recovered by conformation-dependent
antibodies in the presence of CPXV12 could thus be due to either
increased degradation of the HC or a decreased heterotrimer
assembly. Interference with MHC class I assembly, particularly
reduced peptide loading, results in heat-labile heterodimers
(Ljunggren et al., 1990). To examine whether MHC class I mole-
cules were heat labile in CPXV12-expressing cells, we immuno-
precipitated H2-Kb from MC57 cells infected with CPXV, D12,
D203, or D12D203 and pulse-chase labeled for 2 hr. Cell lysates
were either incubated at 37C or kept at 4C prior to immunopre-
cipitation with antibody Y3 and EndoH treatment. EndoH-resis-
tant, heat-stable Kb heterodimers were recovered from both
uninfected cells and cells infectedwith the DKO virus (Figure 6A).
Heat-stable MHC class I were also recovered from D12-infected
cells, although they were EndoH sensitive, consistent with
CPXV203 retaining fully folded, peptide-loaded MHC class I
molecules. In contrast, we did not recover thermostable En-
doH-sensitive Kb from cells infected with either WT or D203.
To determine whether this instability was due to lack of peptides,
we added the Kb-binding peptide SIINFEKL prior to heat chal-
lenge. As shown in Figure 6A, peptide addition prevented disas-
sembly of Kb in lysates from WT and D203-infected MC57 cells,
whereas adding peptide did not increase Kb recovery from unin-
fected cells or cells infected with D12D203 or D12 (Figure 6A).
Similarly, MVA-CPXV12-infected MC57 cells (Figure 6B) con-
tained unstable Kb that was stabilized by SIINFEKL. To extend
these observations to human MHC class I, we cotransfectedCell HostHLA-A3 with N-terminally or C-terminally FLAG-tagged CPXV12
and studied its thermostability in the presence or absence of the
Flu-NP peptide ILRGSVAHK (Bakker et al., 2008) (Figure 6C). In
N-FLAG transfectants, the conformation-specific antibody GAP
precipitated HLA-A3 from lysates incubated at 37C only in the
presence of peptide. As expected, we observed that C-termi-
nally tagged CPXV12 did not destabilize HLA-A3. These data
present strong evidence that CPXV12 prevents peptide loading
of MHC class I and acts by a mechanism distinct from that of
CPXV203, which retains peptide-loaded MHC class I.
CPXV12 Inhibits TAP-Dependent Peptide Translocation
CPXV12-mediated inhibition of peptide loading suggested that
ER retention by CPXV12 was an indirect consequence of
CPXV12 preventing assembly of MHC class I with peptides.
Several steps are involved in the peptide-loading process that
occurs in a multiprotein complex consisting of the peptide trans-
porter TAP, the MHC class I-specific chaperone tapasin, the ER-
resident chaperone calnexin, the thiol-reductase ERp57, and
protein-disulfide isomerase (Raghavan et al., 2008). Since the
most critical step is the translocation of cytosolic peptides by
TAP, we hypothesized that CPXV12 inhibits TAP. We examined
peptide translocation across the ER membrane using a fluores-
cent assay that recovers glycosylated, fluorescently labeled
peptides using the lectin concanavalin A. Upon permeabilization
of the plasma membrane with streptolysin O (SLO), a fluores-
cently labeled nonameric peptide is added, carrying the N-linked
glycosylation sequence NXT/S. Using such peptides, TAP-
dependent peptide translocation can be observed independent
of MHC class I binding, since N-linked glycosylation occurs
exclusively in the ER (Neefjes et al., 1993). We examined TAP
transport in HeLa cells infected with D203 or D12D203. For
control, we included VACV-expressing ICP47 (Banks et al.,
1994), a TAP inhibitor of herpes simplex virus 1 (HSV-1) (Fru¨h
et al., 1995; Hill et al., 1995). Compared to uninfected cells or
cells infected with VACV, infection with VACV-ICP47 reduced
fluorescent peptide recovery by approximately 60% (Figure 7A).
While peptide recovery from cells infected with D12D203 was
comparable to uninfected or VACV-infected, there was a signifi-
cant reduction of peptide transport by D203 by approximately
50%, suggesting that CPXV12 impedes TAP transport. To deter-
mine whether CPXV12 is sufficient for TAP inhibition, we stably
expressed CPXV12 in the human melanoma cell line MJS. Func-
tional expression of CPXV12 was verified by monitoring MHC
class I surface expression (Figure 7B). For comparison, we
used the TAP inhibitor BNLF2a from EBV (Hislop et al., 2007;
Horst et al., 2009). As shown in Figure 7B, CPXV12 reduced
peptide transport by approximately 80%, whereas BNLF2a
reduced peptide transport by about 90%. Thus, we conclude
that CPXV12 inhibits peptide transport by TAP.
Diminished TAP transport could be due to either CPXV12
directly targeting TAP or an indirect consequence of interference
with tapasin function (Garbietal., 2003).Therefore,wedetermined
whether CPXV12 would interfere with TAP-independent peptide
loading in TAP-deficient mouse embryonic fibroblasts (MEFs)
(Van Kaer et al., 1992) infected with VACV-ES-OVA257–264 (Bacik
et al., 1994) expressing ER-targeted SIINFEKL together with
the various CPXV constructs. Both WT and D12 inhibited MHC
class I surface expression measured with an antibody specific& Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc. 439
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A Poxviral TAP InhibitorFigure 6. CPXV12 Inhibits Peptide Loading of MHC Class I
(A and B) H2-Kb thermostability in the presence of virus-expressed CPXV12. MC57 cells were infected with indicated viruses. At 6 hr postinfection, cells were
pulse labeled for 20 min followed by 2 hr chase. Lysates were incubated at indicated temperatures in the presence or absence of the peptide SIINFEKEL.
H2-Kb was immunoprecipitated with mAb Y3 and EndoH treated.
(C) Thermostability of HLA-A3 transfected in HeLa together with CPXV12-N-FLAG or CPXV12-C-FLAG. Cells were labeled as in (A) and incubated at indicated
temperature in the presence or absence of peptide ILRGSVAHK. ‘‘R’’ and ‘‘D’’ refer to EndoH-resistant and digested MHC class I.for the H2-Kb/SIINFEKL complex (Porgador et al., 1997), consis-
tent with CPXV203 preventing intracellular transport of MHC
class I independent of TAP (Figures 7C and S3). In contrast, Kb/
SIINFEKL complexes were observed at the surface of TAP/
MEFs infected with D203 and D12D203, suggesting that
CPXV12 was unable to prevent TAP-independent peptide
loading andMHC class I transport. To further determine whether
CPXV12 could inhibit TAP in the absence of tapasin, we infectedCell Hosttapasin-deficient MEFs with D203 or D12D203 and monitored
total H2-Kb expression. TPN/ MEFs infected with D12D203
expressed reduced levels of H2-Kb compared to WT MEFs
(Figure 7D), since MHC class I molecules are less stable due to
inefficient peptide loading in TPN/ cells (Garbi et al., 2000;
Grandea et al., 2000). However, MHC class I expression was
further reduced when TPN/ MEFs were infected with D203
(Figure 7D), consistent with a lack of peptide supply uponFigure 5. CPXV12 Impairs Intracellular Transport and Steady State Levels of MHC Class I
(A) H2-Kb expression in the presence of CPXV12. MC57 cells were infected with indicated viruses and pulse labeled for 20 min at 6 hr postinfection followed by
2 hr chase. Immunoprecipitated samples were EndoH treated as indicated, separated by SDS-PAGE, and visualized by autoradiography. ‘‘R,’’ ‘‘S,’’ and ‘‘D’’ refer
to EndoH-resistant, sensitive, and digested HC. The reduced amount of MHC class I in EndoH-treated samples is due to reduced protein recovery after EndoH
treatment.
(B) Intracellular transport of HLA-A3 transfected into HeLa cells and infected with WT or recombinant CPXV. At 6 hr postinfection, cells were pulse labeled for
20 min followed by 2 hr chase. HLA-A3 was immunoprecipitated and EndoH treated as indicated.
(C) H2-Kb immunoprecipitation from MC57 cells infected with MVA or MVA expressing CPXV12. Cells were labeled and immunoprecipitated as in (A).
(D) Immunoprecipitation of endogenous HLA-A,B,C in HeLa cells infected with indicated viruses. Cells were pulse labeled for 20 min at 6 hr postinfection and
chased for 2 hr. HLA-A,B,C was immunoprecipitated and then treated with EndoH as in (A).
(E) HeLa cells transiently transfected with CPXV12, CPXV203, or vector control (Mock) were pulse labeled for 20 min at 24 hr posttransfection followed by 2 hr
chase and immunoprecipitation with anti-HLA-A,B,C.
(F) Intracellular and cell surface levels of MHC class I in the presence of transiently expressed CPXV12measured by flow cytometry at 48 hr after HeLa cells were
transfected with pCPXV203 and pCPXV12. Permeabilized cells (intracellular staining) or unfixed cells were stained with anti-HLA-A,B,C. Vector-transfected and
isotype control samples are represented by gray and dashed gray lines, respectively.& Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc. 441
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(A) Peptide transport in the presence of CPXV12. HeLa cells were infected with indicated viruses and at 6 hr postinfection permeabilized with SLO followed by
incubation with peptide FITC-CVNKTERAY in the presence or absence of ATP in transport buffer. Recovered fluorescencewas background (ATP) adjusted and
is shown as percent relative to uninfected cells (±SD).
(B) Peptide transport in CPXV12-expressing cells. Peptide transport was measured as above in MJS cells stably transduced with GFP-expressing control
lentiviruses or lentiviruses expressing either BNLF2a or CPXV12 (left panel). Transduction efficiency was verified by monitoring MHC class I surface levels by
flow cytometry (right panel). CPXV12, BNLF2a, GFP control, and isotype control are represented by red, blue, green, and black lines, respectively.
(C) CPXV12 does not inhibit TAP-independent peptide loading. TAP/ MEFs were infected with VACV-OVA or VACV-ES-OVA together with indicated CPXV
recombinants (moi = 10 each) and simultaneously treated with 25 U/ml IFNg. At 24 hr postinfection, SIINFEKL/H2-Kb complexes were measured with specific
Ab 25.D1.16 by flow cytometry. The percentage of GFP+ cells that were also 25.D1.16-positive is shown, except for WT CPXV showing total 25.D1.16-positive
cells (*).
(D) MHC class I downregulation by CPXV12 does not require tapasin. WT and TPN/MEFs were infected with indicated viruses (moi = 5) in the presence of IFNg,
and surface H2-Kb was monitored by flow cytometry at 24 hr postinfection. Kb expression is shown for GFP+ cells.CPXV12 expression. Taken together, these data indicate that
CPXV12 targets TAP-dependent peptide transport directly and
independent of tapasin function.
DISCUSSION
Our data suggest that CPXV prevents antigen presentation to
CD8+ T cells by expressing two unrelated and independently
acting proteins. CPXV12 limits the TAP-dependent supply of
peptides to the MHC class I peptide-loading complex. Since
empty MHC class I molecules are retained in the ER by tapasin
(Ortmann et al., 1997; Schoenhals et al., 1999) the observed
ER retention by CPXV12 is thus an indirect consequence of
inhibiting peptide loading. Also, the reduction of MHC class I
steady state levels is likely the result of the ultimate degradation
of emptyMHC class I molecules, as reported for cells expressing
ICP47 (Hughes et al., 1997). In contrast, CPXV203 inhibits the
intracellular transport of MHC class I independent of its peptide
loading status via direct binding and KDEL-mediated retrieval
(Byun et al., 2007). However, although each protein acts inde-
pendently, CPXV expressing both ORFs was more efficient in
preventing T cell stimulation than SKOs (Figure 4). Moreover,
both ORFs are coexpressed as immediate early genes (Fig-
ure S2). A possible scenario is that MHC class I escaping442 Cell Host & Microbe 6, 433–445, November 19, 2009 ª2009 ElsCPXV12 (due to incomplete TAP inhibition or TAP-independent
peptide loading or as empty molecules) are then retrieved by
CPXV203. This sequential interference could conceivably take
place in a complex consisting of CPXV12, TAP, and MHC class
I that also binds CPXV203, thus optimizing prevention of antigen
presentation.
Remarkably, CPXV12 and CPXV203 prevent ER exit of both
human and mouse MHC class I. This is in stark contrast to the
limited species specificity observed for most other viral MHC
class I inhibitors, particularly TAP-inhibitory proteins (Ahn et al.,
1996). In many instances, this restriction correlates with the
limited host range of the corresponding viruses. In contrast,
CPXV infects many mammalian species, and this is reflected in
its ability to inhibit both human and mouse MHC class I path-
ways. The availability of two independently acting MHC class I
inhibitors might thus also increase the host range for CPXV.
Furthermore, by independently targeting MHC class I and TAP,
CPXV also counteracts the polymorphism of MHC class I.
Proteins that interact directly with MHC class I often differentially
affect polymorphic MHC class I alleles. Examples are Adeno-
virus E19 (Feuerbach et al., 1994), HCMV US2 and US11 (Barel
et al., 2006; Machold et al., 1997), and MCMV m06 and m152
(Wagner et al., 2002). In contrast, TAP represents a conserved
target.evier Inc.
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Although not every herpesvirus inhibits TAP, TAP inhibitors were
identified for members of each of the a, b, and g subfamilies.
Interestingly, most herpesviral TAP inhibitors are unrelated to
each other, suggesting that TAP inhibition has evolved indepen-
dently multiple times. The repeated occurrence of TAP inhibition
within the herpesvirus family correlates with the ability of most
herpesviruses to establish long-term, persistent infections within
their hosts. The acquisition of multiple TAP inhibitors probably
reflects the enormous immunological pressure exerted by
CD8+ T cells during long-term infection by herpesviruses. In
contrast, OPXVs are typically acute viruses that employ a ‘‘hit
and run’’ strategy to disseminate within a host population. While
OPXV infection often causes significant morbidity, the host
develops long-term protective immunity once the infection is
cleared (Hammarlund et al., 2003). This protective immunity is
considered to be mostly antibody mediated (Edghill-Smith
et al., 2005). However, the fact that CPXV devotes two of its
genes to counteract CD8+ T cells suggests that the cytolytic
T cell immune response also plays a major role in controlling
acute infection with CPXV.
Interestingly, CPXV12 of CPXV-BR seems to be derived by
truncation and mutation from the D10L protein of other CPXV
strains. D10L contains a C-type lectin domain homologous
to host Clr-b, a ligand for the NK cell-inhibitory receptor
NKR-P1B (Voigt et al., 2007). While it is not known whether
D10L activates this inhibitory receptor, NK cell inhibition was
demonstrated for the related protein RCTL in rat CMV (Voigt
et al., 2007). CPXV-BR thus seems to have modified an NK
cell-inhibitory protein to become a T cell evasion protein. This
‘‘exaptation’’ of unrelated viral proteins for TAP inhibition is remi-
niscent of the UL49.5 protein, which functions as a chaperone
for the viral gM protein in all herpesviruses, but TAP inhibition
has been observed for only a few varicelloviruses (Koppers-Lalic
et al., 2005). That TAP can be inhibited by several different
proteins of different evolutionary origin and in entirely unrelated
viral families is probably facilitated by several possible modes
of TAP inhibition. As ABC transporter, TAP pumps peptides
across the ER membrane by ATP hydrolysis. Several of the
multiple steps that are involved in this process can be experi-
mentally distinguished, such as peptide binding, ATP binding,
and ATP hydrolysis. So far, TAP inhibitors can be classified as
inhibitors of peptide binding (ICP47) (Ahn et al., 1996), inhibitors
of ATP binding (US6, EHV UL49.5) (Hewitt et al., 2001; Koppers-
Lalic et al., 2005), or both (BNLF2a) (Hislop et al., 2007). Addition-
ally, TAP degradation has been reported for BHV-1 U49.5
(Koppers-Lalic et al., 2005). While further work will be required
to determine the mechanism of TAP inhibition by CPXV12 in
more detail, its type II transmembrane topology together with
the fact that the ER-lumenal domain seems to be more sensitive
to manipulation than the cytosolic domain renders it likely that
CPXV12 will not prevent peptide binding to TAP, which occurs
in the cytoplasm. In fact, both inhibitors of peptide binding,
ICP47 and BNLF2a, represent short 60–70 amino acid proteins
that act on the cytosolic face of TAP. In contrast, EHV UL49.5
and HCMV US6 both inhibit ATP binding, which is coupled to
peptide translocation, and represent type I transmembrane
proteins that act on the lumenal side of TAP. It is thus possible
that CPXV12 will similarly block ATP binding.Cell HostTruncated gene fragments similar toCPXV12 are widely found
in poxviral genomes (http://www.poxvirus.org) and frequently
represent loss-of-function phenotypes. Our finding suggests
that such truncated ORFs might acquire entirely new, unantici-
pated functions. It is thus important to consider this evolutionary
‘‘genetic debris’’ when considering poxviral proteomes and their
associated function. Since TAP homologs are present in all
vertebrate genomes and since all vertebrates are potential hosts
of herpes and poxviruses, our data further suggest that TAP
inhibition might be more widespread than previously thought,
particularly in large DNA viruses.
EXPERIMENTAL PROCEDURES
Cells and Viruses
HeLa, telomerized human fibroblast (THF), HEK293T, MC57G mouse fibro-
blast, and BHK-21 cells were maintained in DMEM (Mediatech, Inc.; Mana-
ssas, VA) supplemented with 10% FBS (HyClone; Logan, UT). WT, TAP/,
and TPN/ MEFs were obtained from Ann Hill (OHSU) and maintained in
complete DMEM as above. To induce MHC class I expression, MEFs were
treated with 25 U/ml recombinant mouse IFNg (R&D Systems; Minneapolis).
A20 mouse B lymphoma cells and MJS human melanoma cells were grown
in 10% FBS-RPMI 1640 medium (HyClone). BSC40 (African Green Monkey
kidney cells) were grown in MEM (Mediatech). VACV-ICP47, VACV-OVA,
and VACV-ES-OVA were obtained from Jon Yewdell (NIH). VACV, MVA, and
CPXV were propagated in BSC40 cells maintained in MEM (5% FBS MEM).
MVA was amplified in BHK-21 cells incubated in DMEM (5% FBS). Viruses
were purified using standard protocols. Briefly, infected cell lysates were
precleared and layered onto 36% sucrose cushion. The virus was isolated
by centrifugation at 40,0003 g for 80 min, resuspended in 1 mM Tris-HCl
(pH 8.0), and titered. For ICCS, virus was additionally purified by centrifugation
(22,5003 g, 40 min) through a 25%–40% continuous sucrose gradient.
Human Subjects and Animals
VACV-immune subjects provided informed written consent before signing
research authorization forms that complied with the US Health Insurance
Portability and Accountability Act in addition to a medical history question-
naire. These studies were approved by the Institutional Review Board of
OHSU. Female BALB/c mice at 5 months of age (Jackson Laboratory) were
infected intraperitoneally (i.p.) with 23 106 pfu/mouse of VACV-WR. All animal
experiments were reviewed and approved by the OHSU Institutional Animal
Care and Use Committee.
Flow Cytometry
Cells were labeled with Phycoerythrin (PE)-conjugated monoclonal antibodies
(mAbs) specific for HLA-A,B,C (W6/32, eBioscience; San Diego, CA), CD44
(clone 515, BD Biosciences), or FLAG epitope (Invitrogen). Alternatively, bioti-
nylatedW6/32was used followed by Allophycocyanin-conjugated streptavidin
(eBioscience) as a secondary reagent. MC57G cells were labeled with primary
mouse anti-Kb (Y3, ATCC) and secondary chicken anti-mouse antibodies
conjugated to Alexa Fluor 647 (Invitrogen). MEF cells were labeled with Allo-
phycocyanin-conjugated anti-H2-Kb-SIINFEKL complex, clone 25.D1.16
(eBioscience). For intracellular staining, the cells were permeabilized with Cy-
tofix/Cytoperm (BD Biosciences) prior to antibody staining. Flow cytometry
was performed using a FACSCalibur (BD Biosciences) and analyzed with
FlowJo software (Tree Star; Ashland, OR).
In Vitro Translation
mRNAwas transcribed with SP6 RNA polymerase (Promega Biosciences; San
Luis Obispo, CA) and translated in rabbit reticulocyte lysate (Skach, 1998).
Proteinase K digests were performed as indicated in the same reference.
SP6 transcription vectors for CFP and prolactin were kindly provided by Bill
Skach (OHSU). Samples were added to SDS loading buffer and electrophor-
esed on a 16.5% Tris-tricine gel, followed by gel drying and autoradiography.
Microsome pelleting was performed by loading 2 ml of the translation reaction
onto a 100 ml 0.5 M sucrose cushion and centrifuging the sample for 10 min& Microbe 6, 433–445, November 19, 2009 ª2009 Elsevier Inc. 443
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(Beckman Coulter; Fullerton, CA). Supernatants were removed, and pellets
were resuspended in 10 ml of 1% SDS, 0.1 M Tris (pH 8.0) mixed with SDS
loading buffer and analyzed by SDS-PAGE and autoradiography.
ICCS
Human CD8+ T Cells
PBMCs were infected with virus at an moi of 0.3–0.9 for 12 hr, treated with
Brefeldin A (BFA) (ICN Biomedicals; Costa Mesa, CA) for an additional 6 hr,
and stained with anti-CD8b (2ST8.5H7, Beckman Coulter) and anti-CD4
(L200, BD Biosciences). Thereafter, the cells were fixed, permeabilized, and
stained intracellularly using antibodies to IFNg (4S.B3, eBioscience) and
TNF-a (Mab11, eBioscience). Samples were acquired on an LSRII (BD Biosci-
ences; 106 events/sample) and analyzed using FlowJo software. Nonviable
cells were excluded using a live cell gate based on the viability stain Aqua
(LIVE/DEAD Fixable Dead Cell Stain, Invitrogen), followed by an optimized
lymphocyte gate based on forward and side scatter characteristics. The
number of virus-specific IFNg+ TNF-a+ T cells was determined after gating
on live CD4CD8b+ T cells and subtracting the number of IFNg+ TNF-a+ events
from uninfected cultures. To determine efficiency of viral infection and
measure MHC class I expression, the cells were stained with antibodies
specific for CD14 (RMO52, Immunotech; Marseille, France) and HLA-A,B,C
(W6/32, BioLegend; San Diego, CA). Thereafter, the cells were fixed, permea-
bilized, and stained with biotinylated rabbit polyclonal antibodies against
OPXV antigens (ViroStat; Portland, ME) and streptavidin-PECy7. Samples
were acquired on an LSRII (3 3 105 events/sample) and analyzed using
FlowJo software.
Murine CD8+ T Cells
Splenocytes were isolated from VACV-infected mice (2 3 106 pfu/mouse) at
8 days postinfection and analyzed as described (Dasgupta et al., 2007).
A20 cells (5 3 105), uninfected or infected with virus at an moi of 5 for 16 hr,
were mixed with 1 3 106 splenocytes and incubated in the presence of BFA
for 6 hr. Following staining with anti-CD8 (5H10, Invitrogen), cells were fixed,
permeabilized, and labeled intracellularly with antibodies to IFNg (XMG1.2,
BD Biosciences) and TNF-a (MP6-XT22, BioLegend). The samples were
acquired and analyzed as described above.
Pulse-Chase and Thermostability Assay
Metabolic labeling was carried out as described (Dasgupta et al. 2007). Briefly,
HeLa and MC57G cells were labeled with EXPRE35S35S Protein Labeling Mix
(PerkinElmer; Waltham, MA) at 100–300 mCi/106 cells for 20–30 min. Upon
chase, cells were lysed in 1%NP-40 PBS (pH 7.4) with protease inhibitor cock-
tail (Roche Applied Science; Mannheim, Germany). Postnuclear lysates were
precleared with Protein A/G PLUS-Agarose (Santa Cruz Biotechnology; Santa
Cruz, CA) and incubated with antibodies to HLA-A,B,C (W6/32, ATCC), HLA-
A3 (GAP A3, ATCC), H2-Kb (Y3, ATCC), or FLAG epitope (Sigma-Aldrich)
and captured with Protein A/G. The immunoprecipitates were treated with
10mU EndoH (Roche), separated by SDS-PAGE, and detected by autoradiog-
raphy. Protein bands were quantified with ImageQuant (GE Healthcare Life
Sciences; Piscataway, NJ). The half-life and corresponding R2 value of
CPXV12 were calculated with Prism (Graphpad; San Diego, CA).
The thermostability assay was done according to Ljunggren et al. 1990.
Briefly, labeled cell lysates were precleared with protein A agarose beads
at 4C overnight in the presence of either 10 mM SIINFEKL (GenScript; Piscat-
away, NJ) or 20 mM of the Influenza-NP peptide ILRGSVAHK (GenScript)
(Bakker et al., 2008). Thereafter, the lysates were kept at 37C for 1 hr and
then returned to 4C for 1 hr, followed by immunoprecipitation.
Peptide Transport Assay
Cells were washed with ice-cold PBS (pH 7.4), trypsinized, and permeabilized
with SLO (Murex Diagnostics; Dartford, UK). The assay was carried out in trip-
licates using 450 pmol of fluorescein isothiocyanate (FITC)-conjugated
CVNKTERAY peptide per 2 3 106 cells in the presence or absence of
10 mM ATP as described (Koppers-Lalic et al., 2005). Fluorescence intensity,
indicative of the amount of glycosylated peptides captured with Concanavalin
A Sepharose beads (GE Healthcare), was measured at the excitation wave-
length of 490 nm and the emission wavelength of 525 nm.444 Cell Host & Microbe 6, 433–445, November 19, 2009 ª2009 ElsImmunofluorescence Staining for Confocal Laser Scanning
Microscopy
HeLa cells were transfected with plasmid constructs using Lipofectamine
2000 (Invitrogen). At 48 hr posttransfection, cells were fixed/permeabilized
with 100% methanol for 10 min and blocked in 2% bovine serum albumin
(BSA)-PBS (P-BSA, pH 7.4). The cells were stained with primary mouse
anti-FLAG (Sigma) and rabbit anti-calreticulin (Novus Biologicals; Littleton,
CO), anti-ERGIC57 (Sigma), and anti-Giantin (Abcam; Cambridge, MA) and
secondary anti-mouse or anti-rabbit antibodies conjugated to Alexa Fluor
594 and Alexa Fluor 488 (Invitrogen), respectively. Coverslips were mounted
on slides in ProLong Gold antifade reagent with 4,6-diamidino-2-phenylindole
(DAPI) (Invitrogen) and analyzed with a Leica TCS SP laser scanning micro-
scope.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, two tables, and three figures and can be found online at
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